[go: up one dir, main page]

MX2023006083A - Npp1 para usarse en el tratamiento de calcificacion de tejidos. - Google Patents

Npp1 para usarse en el tratamiento de calcificacion de tejidos.

Info

Publication number
MX2023006083A
MX2023006083A MX2023006083A MX2023006083A MX2023006083A MX 2023006083 A MX2023006083 A MX 2023006083A MX 2023006083 A MX2023006083 A MX 2023006083A MX 2023006083 A MX2023006083 A MX 2023006083A MX 2023006083 A MX2023006083 A MX 2023006083A
Authority
MX
Mexico
Prior art keywords
calcification
methods
treating tissue
npp1
tissue calcification
Prior art date
Application number
MX2023006083A
Other languages
English (en)
Inventor
Anthony Quinn
Nelson Hsia
Tayeba Khan
Gregory Grabowsky
Zhiliang Cheng
W Charles O'neill
Kym Lynette ASKEW
Original Assignee
Alexion Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharma Inc filed Critical Alexion Pharma Inc
Publication of MX2023006083A publication Critical patent/MX2023006083A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04001—Phosphodiesterase I (3.1.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/01—Hydrolases acting on acid anhydrides (3.6) in phosphorus-containing anhydrides (3.6.1)
    • C12Y306/01009—Nucleotide diphosphatase (3.6.1.9), i.e. nucleotide-pyrophosphatase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona composiciones para usarse en el tratamiento de la deficiencia de NPP1 o una enfermedad asociada con NPP1 tal como la calcificación arterial idiopática infantil (IIAC), pseudoxantoma elástico, calcificación vascular en enfermedad renal crónica (VCCKD), resistencia a la insulina, raquitismo hipofosfatémico, isquemia del miocardio, calcificación de articulaciones, estrías angioides, y osificación del ligamento longitudinal posterior de la espina.
MX2023006083A 2014-12-19 2017-06-15 Npp1 para usarse en el tratamiento de calcificacion de tejidos. MX2023006083A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462094943P 2014-12-19 2014-12-19
US201562249781P 2015-11-02 2015-11-02

Publications (1)

Publication Number Publication Date
MX2023006083A true MX2023006083A (es) 2023-06-19

Family

ID=56127864

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2017007946A MX2017007946A (es) 2014-12-19 2015-12-18 Metodos para tratar la calcificacion de tejidos.
MX2022011281A MX2022011281A (es) 2014-12-19 2017-06-15 Npp1 para usarse en el tratamiento de calcificacion de tejidos.
MX2023006083A MX2023006083A (es) 2014-12-19 2017-06-15 Npp1 para usarse en el tratamiento de calcificacion de tejidos.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2017007946A MX2017007946A (es) 2014-12-19 2015-12-18 Metodos para tratar la calcificacion de tejidos.
MX2022011281A MX2022011281A (es) 2014-12-19 2017-06-15 Npp1 para usarse en el tratamiento de calcificacion de tejidos.

Country Status (15)

Country Link
US (2) US10493135B2 (es)
EP (3) EP3967755B1 (es)
JP (3) JP7685309B2 (es)
KR (2) KR20250111233A (es)
CN (1) CN107109381A (es)
AU (1) AU2015364411A1 (es)
BR (1) BR112017012928A2 (es)
CA (1) CA2971414A1 (es)
CO (1) CO2017006032A2 (es)
ES (2) ES2899895T3 (es)
HK (1) HK1245662A1 (es)
MX (3) MX2017007946A (es)
PL (1) PL3967755T3 (es)
RU (1) RU2770698C2 (es)
WO (1) WO2016100803A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3014398T3 (en) * 2013-02-13 2025-04-22 Univ Yale Compositions for treating pathological calcification and ossification
HK1245662A1 (zh) 2014-12-19 2018-08-31 Alexion Pharmaceuticals, Inc. 治疗组织钙化的方法
EP3298140B1 (en) 2015-05-19 2024-04-24 Yale University Compositions for treating pathological calcification conditions, and methods using same
CA3005142A1 (en) 2015-11-20 2017-05-26 Yale University Compositions for treating ectopic calcification disorders, and methods using same
EP3471747A1 (en) 2016-06-16 2019-04-24 Alexion Pharmaceuticals, Inc. Methods of treating myointimal proliferation
JP2019532915A (ja) 2016-08-05 2019-11-14 イエール ユニバーシティ 小児鎌状赤血球貧血患者における脳卒中予防のための組成物および方法
WO2019067502A1 (en) * 2017-09-27 2019-04-04 Alexion Pharmaceuticals, Inc. METHODS FOR IMPROVING CARDIOVASCULAR FUNCTION AND TREATING CARDIOVASCULAR DISEASE USING RECOMBINANT ECTO-NUCLEOTIDE PYROPHOSPHATASE / PHOSPHODIESTERASE
JP2021523139A (ja) * 2018-05-08 2021-09-02 イエール ユニバーシティ 腎石症の進行を遅らせるための組成物および方法
CN112930397B (zh) * 2018-08-31 2025-05-09 耶鲁大学 Enpp1多肽及其使用方法
EP3911153A4 (en) * 2019-01-18 2022-12-21 Inozyme Pharma, Inc. TREATMENT OF DISEASES INVOLVING ENPP1 OR ENPP3 DEFICIENCY
CN113416258B (zh) 2019-10-24 2023-08-29 北京免疫方舟医药科技有限公司 一种多特异性抗体及其制备方法和用途
WO2021252549A1 (en) * 2020-06-09 2021-12-16 Inozyme Pharma, Inc. Soluble enpp1 or enpp3 proteins and uses thereof
MX2023005836A (es) * 2020-11-19 2023-08-17 Inozyme Pharma Inc Tratamiento para la deficiencia de enpp1 y la deficiencia de abcc6.

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US6267964B1 (en) 1989-08-01 2001-07-31 Affibody Technology Sweden Ab Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
WO1999024565A1 (en) 1997-11-07 1999-05-20 Transplantation Technologies Inc. Methods and compositions for immunomodulation
US6272859B1 (en) 1998-10-02 2001-08-14 Caterpillar Inc. Device for controlling a variable geometry turbocharger
AU784285B2 (en) 1999-12-24 2006-03-02 Genentech Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
US6780587B2 (en) 2000-02-23 2004-08-24 Pxe International, Inc. Methods for diagnosing Pseudoxanthoma elasticum
WO2002076489A1 (en) 2001-03-09 2002-10-03 Dyax Corp. Serum albumin binding moieties
US7858297B2 (en) 2001-12-18 2010-12-28 Centre National De La Recherche Scientifique Cnrs Chemokine-binding protein and methods of use
AU2003213246A1 (en) 2002-02-21 2003-09-09 University Of Virginia Patent Foundation Bone targeting peptides
AU2003210806A1 (en) 2002-03-05 2003-09-22 Eli Lilly And Company Heterologous g-csf fusion proteins
JP2006512050A (ja) 2002-06-21 2006-04-13 ダイアックス、コープ 血清タンパク質結合標的特異的リガンドとその同定方法
CA2554089C (en) 2004-02-09 2013-10-22 Human Genome Sciences, Inc. Albumin fusion proteins
US20050287284A1 (en) 2004-06-28 2005-12-29 Shukla Triveni P Processed meats comprising dietary fiber gel
US20090142347A1 (en) 2004-09-29 2009-06-04 The Burnham Institute For Medical Research Tissue-Nonspecific Alkaline Phosphatase (TNAP): a Therapeutic Target for Arterial Calcification
US20100113339A1 (en) 2006-09-08 2010-05-06 Ablynx N. V. Serum albumin binding proteins with long half-lives
WO2012125182A1 (en) * 2011-03-11 2012-09-20 Synageva Biopharma Corp Npp1 fusion proteins
WO2011113027A2 (en) 2010-03-12 2011-09-15 Synageva Biopharma Corp Npp1 fusion proteins
ES3014398T3 (en) 2013-02-13 2025-04-22 Univ Yale Compositions for treating pathological calcification and ossification
HK1245662A1 (zh) * 2014-12-19 2018-08-31 Alexion Pharmaceuticals, Inc. 治疗组织钙化的方法
EP3298140B1 (en) * 2015-05-19 2024-04-24 Yale University Compositions for treating pathological calcification conditions, and methods using same
CA3005142A1 (en) 2015-11-20 2017-05-26 Yale University Compositions for treating ectopic calcification disorders, and methods using same

Also Published As

Publication number Publication date
EP4438118A2 (en) 2024-10-02
CO2017006032A2 (es) 2017-10-20
WO2016100803A3 (en) 2016-08-04
ES2981606T3 (es) 2024-10-09
EP4438118A3 (en) 2024-12-04
WO2016100803A2 (en) 2016-06-23
KR20250111233A (ko) 2025-07-22
CA2971414A1 (en) 2016-06-23
HK1245662A1 (zh) 2018-08-31
EP3967755A1 (en) 2022-03-16
ES2899895T3 (es) 2022-03-15
MX2017007946A (es) 2017-09-15
RU2017119466A3 (es) 2019-12-20
AU2015364411A1 (en) 2017-06-08
CN107109381A (zh) 2017-08-29
JP2024010052A (ja) 2024-01-23
EP3234116B1 (en) 2021-09-08
JP7685309B2 (ja) 2025-05-29
KR20170095367A (ko) 2017-08-22
JP2022003048A (ja) 2022-01-11
JP2018500315A (ja) 2018-01-11
MX2022011281A (es) 2022-10-18
PL3967755T3 (pl) 2024-08-19
EP3234116A4 (en) 2018-08-01
KR102833432B1 (ko) 2025-07-14
RU2017119466A (ru) 2019-01-21
US20180318400A1 (en) 2018-11-08
EP3967755B1 (en) 2024-03-27
RU2770698C2 (ru) 2022-04-21
USRE49529E1 (en) 2023-05-16
EP3234116A2 (en) 2017-10-25
US10493135B2 (en) 2019-12-03
BR112017012928A2 (pt) 2018-05-15

Similar Documents

Publication Publication Date Title
MX2023006083A (es) Npp1 para usarse en el tratamiento de calcificacion de tejidos.
MX2019008085A (es) Antagonistas de activina-actrii y usos para tratar transtornos oseos y otros.
MX2023000796A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
SV2017005420A (es) Composiciones y métodos de uso para tratar trastornos metabólicos
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
DOP2017000025A (es) Composiciones y métodos de uso para tratar trastornos metabólicos
MX389207B (es) Composiciones de nicotinamida ribósido y pteroestilbeno y métodos para el tratamiento de trastornos de la piel.
LT3668513T (lt) Piruvatkinazės aktyvatoriai, skirti panaudoti kraujo sutrikimų gydymui
EA201790273A1 (ru) Флагеллиновые композиции и их применение
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
MX384264B (es) Material anisotropico biocompuesto, implantes medicos que lo comprenden y metodos para el tratamiento del mismo
BR112016022742A2 (pt) composições e métodos para modular a expressão de receptor de hormônio do crescimento
MX2019013808A (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer.
MX2017016134A (es) Aril dihidro-2h-benzo[b][1,4]oxazina sulfonamida y compuestos relacionados para uso como agonistas de rory y el tratamiento de enfermedad.
MX2018000352A (es) 4-azaindoles sustituidos y su uso como moduladores del receptor glun2b.
MX394222B (es) Nuevos profarmacos polimericos de la hormona del crecimiento humana (hgh).
MX356755B (es) Compuestos de tipo fumagilol y metodos para su elaboración y uso.
WO2017079570A3 (en) Splise-switching oligonucleotides and methods of use
MX2019003619A (es) Formulaciones de bromocriptina.
MX381544B (es) Composición de células estromales mesenquimatosas para usare en el tratamiento de la sepsis en un sujeto.
MX2016015378A (es) Uso de eribulina en el tratamiento de cancer.
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
CL2017001407A1 (es) Antagonista de a2a de dosis baja para el tratamiento de tdah y la enfermedad de parkinson
MA39718A (fr) Compositions et méthodes d'utilisation de celles-ci
MX2018003317A (es) Celulas t modificadas que tienen propiedades anti-fuctacticas y sus usos.